Bridge Gap Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 24-12-2024
- Paid Up Capital ₹ 0.50 M
as on 24-12-2024
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.62 Cr
as on 24-12-2024
- Revenue 13.70%
(FY 2022)
- Profit 67.87%
(FY 2022)
- Ebitda 26.65%
(FY 2022)
- Net Worth 28.46%
(FY 2022)
- Total Assets -3.61%
(FY 2022)
About Bridge Gap Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹3.62 Cr.
Kiran Vakkalanka, Chinnababu Sunkavalli, and Ramesh Teegala serve as directors at the Company.
- CIN/LLPIN
U85100TG2014PTC092530
- Company No.
092530
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jan 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Bridge Gap Lifesciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kiran Vakkalanka  | Director | 28-Aug-2020 | Current |
| Chinnababu Sunkavalli | Director | 28-Jan-2014 | Current |
| Ramesh Teegala | Director | 18-Mar-2016 | Current |
Financial Performance of Bridge Gap Lifesciences.
Bridge Gap Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 13.7% increase. The company also saw a substantial improvement in profitability, with a 67.87% increase in profit. The company's net worth Soared by an impressive increase of 28.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bridge Gap Lifesciences?
In 2023, Bridge Gap Lifesciences had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Excel Soft Services (India) Private LimitedActive 19 years 7 monthsChinnababu Sunkavalli is a mutual person
Davanagere Cancer Center Private LimitedActive 7 years 1 monthKiran Vakkalanka and Chinnababu Sunkavalli are mutual person
- Bg-Radio Nuclear Pet Imaging LlpActive 1 year 4 months
Kiran Vakkalanka and Chinnababu Sunkavalli are mutual person
- Khammam Cancer Hospital Private LimitedActive 7 years 2 months
Kiran Vakkalanka and Chinnababu Sunkavalli are mutual person
Charges (Loans)
₹3.62 Cr
₹0
Charges Breakdown by Lending Institutions
- State Bank Of India : 3.62 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Jan 2017 | State Bank Of India | ₹3.62 Cr | Open |
How Many Employees Work at Bridge Gap Lifesciences?
Bridge Gap Lifesciences has a workforce of 18 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bridge Gap Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bridge Gap Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
